SIRPant Immunotherapeutics is spearheading the development of macrophage-based cell therapies for the treatment of solid tumors. Leveraging our deep understanding of the biology of myeloid cells—the cells that drive immune responses—SIRPant engineers specially-equipped macrophages from a patient’s own blood cells without any genetic modifications and then provides those cells back to the patient. In pre-clinical studies, this approach has been shown to generate polyclonal tumor neo-antigen-specific killer T cell responses as well as polyclonal tumor neo-antigen-specific antibody responses, leading to complete resolution of treated tumors. This also yields an adaptive immune response that is elaborated in space (targeting metastatic lesions) and time (providing long-term immunity to prevent recurrence). In addition, because this therapeutic approach does not target specific singular tumor-associated antigens, SIRPant technology provides a highly modular platform that is applicable across many solid tumor types, without requiring pre-identification of target tumor antigens in the patient.